[REQ_ERR: 404] [KTrafficClient] Something is wrong. Enable debug mode to see the reason.

Destiny pan tumor 02

This study will enroll 7 tumor-specific cohorts: urothelial for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02). DESTINY-PanTumor 02 is an open-label, multi center, multi cohort study that will investigate the safety and efficacy of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2 expressing tumours; these tumour cohorts include urothelial (bladder) cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare . Enrolment into DESTINY-Breast01 was completed in September with ADCs are targeted cancer medicines that deliver cytotoxic. Here we describe the phase 2 DESTINY-PanTumor02 trial evaluating T-DXd in patients with select HER2-expressing solid tumors. . Jul 22, This study will enroll 7 tumor-specific cohorts: urothelial for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02). If you choose to join this study you will: Have an infusion of the study drug (trastuzumab deruxtecan) once every 3 weeks -Provide old tumor tissue -Have an eye exam -Have physical exams, blood and urine tests -Have imaging scans (CT and/or MRI). AstraZeneca DESTINY-PanTumor02 (HER2+ Tumors) What is the Purpose of this Study? A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DSa) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) Actual Study Start Date: August 18, Estimated Primary Completion Date: June 16, Estimated Study Completion Date: June 16, Median time to first onset was months (range: to ). Neutropenia. In DESTINY-Gastric01, of the patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU mg/kg, ILD occurred in 10% of patients. Locally Advanced or Metastatic Gastric Cancer. DESTINY-PanTumor02 is an open-label, multicenter, multicohort, phase 2 study evaluating T-DXd for the treatment of patients with select HER2-expressing locally. HER2 overexpression and/or mutations are also observed in tumors other than breast and gastric cancers, such as non–small cell lung cancer (NSCLC) and.

  • Jan 19, Methods: DESTINY-PanTumor02 (NCT) is an open-label, multicenter, multicohort, phase 2 study evaluating T-DXd for the treatment of  .
    • A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DSa) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) Actual Study Start Date: August 18, Estimated Primary Completion Date: June 16, Estimated Study Completion Date: June 16, If you choose to join this study you will: Have an infusion of the study drug (trastuzumab deruxtecan) once every 3 weeks -Provide old tumor tissue -Have an eye exam -Have physical exams, blood and urine tests -Have imaging scans (CT and/or MRI). Home AstraZeneca DESTINY-PanTumor02 (HER2+ Tumors) What is the Purpose of this Study? Official Title: A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DSa) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02). Trastuzumab Deruxtecan (DS), ENHERTU®, Non-small Cell Lung Cancer, DESTINY-Lung jRCTOpen new window. DESTINY-PanTumor02 is an open-label, multicenter, multicohort, phase 2 study evaluating T-DXd for the treatment of patients with select HER2-expressing locally  . Het doel is ook om de onderzochte kankers en geassocieerde gezondheidsproblemen beter te begrijpen. We kunnen van tevoren niet zeggen hoe lang het onderzoek gaat duren. Onderzoek naar de werkzaamheid en veiligheid van Trastuzumab Deruxtecan bij patiënten met vergevorderde kanker. Meerdere kankersoorten: Destiny-PanTumor02 studie. DESTINY-CRC02 is a global, phase 2 trial evaluating the efficacy and safety of two doses ( mg/kg or mg/kg) of ENHERTU in patients with HER2 overexpressing BRAF wild-type, RAS wild-type or. Pan_02 has very low sensitivity to chemotherapeutics therefore it is very similar to human pancreatic cancers. Materials and methods: Mice were subcutaneously injected with different number of cells and tumor growth was measured. Aim: The aim of this study was to investigate and describe basic features of Pan_02 murine pancreatic ade- nocarcinoma tumor model. Please note - this trial is no longer recruiting patients. A trial of trastuzumab deruxtecan for cancers that have a large amount of HER2 (DESTINY-PanTumour02). Trastuzumab deruxtecan (T-DXd) is a novel HER2-directed antibody drug conjugate showing significant anti-tumor activity in heavily pre-treated HER2-positive. High-dose radiotherapy in trimodality treatment of Pancoast tumors results epidermal growth factor receptor mutation--diversity, ductility, and destiny. DESTINY-PanTumor02 TRIAL OVERVIEW Confirmed ORR per RECIST is the percentage of patients with Complete Response or Partial Response that is subsequently  . ACE-Pan tumor First Posted: September 13, Key Record Dates: Last Update Posted: April 28, Last Verified: April Individual Participant Data (IPD. Progressed following prior treatment or who have no satisfactory alternative treatment option. Prior HER2 targeting therapy is permitted. Cohort 7: Rare tumors: This cohort will consist of patients with tumors that express HER2, excluding the tumors mentioned above, and breast, non-small cell lung cancer, gastric cancer, and colorectal cancer. DESTINY-Breast01 (NCT) is an open-label, international, multicenter, phase 2 study of T-DXd in patients with HER2 positive metastatic breast cancer (MBC). A Study of BMS-  . Please click on individual studies to see what tumors/conditions each study is recruiting for. CA Recruiting. Official Title: A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DSa) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02). DSa) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02). bladder, cervical, endometrial, ovarian, and pancreatic cancers. Meerdere kankersoorten: Destiny-PanTumor02 studie Onderzoek naar de werkzaamheid en veiligheid van Trastuzumab Deruxtecan bij patiënten met vergevorderde kanker Doel onderzoek Het doel van dit onderzoek is uitzoeken hoe werkzaam en veilig het onderzoeksmiddel Trastuzumab Deruxtecan (T-DXd) is voor de behandeling van verschillende kankersoorten. “A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd. DVC (Destiny pan tumor 02). CA Recruiting. A Study of BMS-. Please click on individual studies to see what tumors/conditions each study is recruiting for. A Phase 2, Multicenter, Open-label Study. Sep 7, DESTINY-Gastric02 phase 2 trial in patients with HER2 positive unresectable Pan. -. . Tumor. Materials and methods: Mice were subcutaneously injected with different number of cells and tumor growth was measured. Aim: The aim of this study was to investigate and describe basic features of Pan_02 murine pancreatic ade- nocarcinoma tumor model. Pan_02 has very low sensitivity to chemotherapeutics therefore it is very similar to human pancreatic cancers. They must have human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction (GEJ) cancer: that cannot be removed surgically; that has moved to other parts of the body. This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer. DESTINY-PanTumor02 TRIAL OVERVIEW Confirmed ORR per RECIST is the percentage of patients with Complete Response or Partial Response that is subsequently. DESTINY-Breast02 will compare the efficacy and safety of T-DXd with those of the investigator's choice of therapy in patients with HER2-positive. The pan-histological expansion of antibody–drug conjugates poses ( mg/kg); D. DESTINY-Breast03 ( mg/kg); E. DESTINY-Gastric02 ( mg/kg); F. .
  • The HER2CLIMB results Standard-of-care treatment for patients with HER2-positive MBC is first-line trastuzumab plus pertuzumab and a taxane, followed by second-line trastuzumab emtansine for patients who have disease progression. In DESTINY-Breast01, trastuzumab deruxtecan showed durable antitumour activity.
    • The DESTINY-Lung01 trial evaluated T-DXd in HER2 -positive non-squamous non-small cell lung cancer (NSCLC) and reported a progression-free survival of 14 months in HER2 -mutated NSCLC, earning its breakthrough designation by the FDA. In this review, we will discuss the structural characteristics, pharmacodynamics, and pharmacokinetics of T-DXd. The initial studies of trastuzumab in early breast cancer in randomized controlled trials DESTINY-Breast02 and DESTINY-Breast . Aug 25, A Phase Study of ST in Patients With Advanced Solid Tumors That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]. et al.,; for the DESTINY-Lung01 Trial Investigators. 1,2,3 For patients. Lung cancer is the leading cause of cancer death among both men and women, and accounts for about one-fifth of all cancer deaths globally, with 80 to 85% classified as NSCLC. Trastuzumab deruxtecan (DS) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic. Pan-cancer analysis shows that the most common HER2 mutations are SF/Y (%), Trastuzumab deruxtecan (DS), DESTINY-Breast01 (NCT). Methods: DESTINY-PanTumor01 is an open-label, multicenter, single-arm, phase 2 study evaluating T-DXd for the treatment of patients with unresectable and/or metastatic solid tumors (excluding non-small cell lung cancer) harboring prespecified HER2-activating mutations. Patients (N≈) are required to have progressed following prior treatment for advanced or metastatic disease or have no satisfactory alternative treatment options. Here we describe the DESTINY-PanTumor01 trial (NCT). Among the 33 patients with CNS metastases at baseline, median progression. A total of 47 patients (52%) had died as of the data cutoff, and the other patients continue to be followed for survival.